Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, et al.
Molecular Metabolism (2017) Vol. 6, Iss. 5, pp. 440-446
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel, Gerald I. Shulman
Cell Metabolism (2017) Vol. 27, Iss. 1, pp. 22-41
Open Access | Times Cited: 608
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Lili Niu, Philipp E. Geyer, Nicolai J. Wewer Albrechtsen, et al.
Molecular Systems Biology (2019) Vol. 15, Iss. 3
Open Access | Times Cited: 234
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller, Christoffer Clemmensen, Brian Finan, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 712-746
Open Access | Times Cited: 163
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 128
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao, Qingtong Zhou, Zhaotong Cong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 94
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen, Brian Finan, Timo D. Müller, et al.
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 2, pp. 90-104
Closed Access | Times Cited: 104
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
Rongjun He, Brian Finan, John P. Mayer, et al.
Molecules (2019) Vol. 24, Iss. 10, pp. 1855-1855
Open Access | Times Cited: 90
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 51
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 27
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
Endocrinology and Metabolism (2024) Vol. 39, Iss. 1, pp. 12-22
Open Access | Times Cited: 14
Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice
Weiting Hu, Wenyu Gong, Fan Yang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113937-113937
Closed Access | Times Cited: 1
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Marta Seghieri, Alexander S. Christensen, Andreas Andersen, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 78
Leveraging the Gut to Treat Metabolic Disease
Ruth E. Gimeno, Daniel A. Briere, Randy J. Seeley
Cell Metabolism (2020) Vol. 31, Iss. 4, pp. 679-698
Open Access | Times Cited: 69
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kook Hwan Kim, Myung‐Shik Lee
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 67
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Silvano Paternoster, Marco Falasca
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 65
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
David S. Mathiesen, Jonatan I. Bagger, Natasha C. Bergmann, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4092-4092
Open Access | Times Cited: 62
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
André F. Batista, Victor Bodart‐Santos, Fernanda G. De Felice, et al.
CNS Drugs (2018) Vol. 33, Iss. 3, pp. 209-223
Closed Access | Times Cited: 60
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Nathalia Romanelli Vicente Dragano, Johan Fernø, Carlos Diéguez, et al.
Neuroscience (2020) Vol. 437, pp. 215-239
Closed Access | Times Cited: 58
The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
Sravan Thondam, Daniel J. Cuthbertson, John Wilding
Peptides (2019) Vol. 125, pp. 170208-170208
Closed Access | Times Cited: 55
Page 1 - Next Page

Scroll to top